Imatinib (IM) discontinuation in chronic myeloid leukemia (CML): A pharmacogenetic score for patients with durable complete molecular response (CMR)
2016
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI